National Institute on Drug Abuse; Notice of Closed Meeting, 36612 [2019-16021]
Download as PDF
<![CDATA[
36612
Federal Register / Vol. 84, No. 145 / Monday, July 29, 2019 / Notices
2019. The closed session is amended to
end at 9:30 a.m. and the open session is
amended to begin at 9:30 a.m. The
meeting is partially closed to the public.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
National Institute on Alcohol Abuse
and Alcoholism; Amended Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The cooperative agreement
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the cooperative agreement applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Notice is hereby given of a change in
the meeting of the Board of Scientific
Counselors, NIAAA, September 18,
2019, 8:30 a.m. to September 18, 2019,
3:30 p.m., National Institutes of Health,
Building 10, Conference Room I–2330,
10 Center Drive, Bethesda, MD 20892
which was published in the Federal
Register on February 26, 2019, 84 FR
6155.
This meeting notice is amended to
change the meeting location from
Building 10, Conference Room I–2330,
10 Center Drive, Bethesda, MD 20892 to
5625 Fishers Lane, 5th Floor Conference
Room, Rockville, MD 20852. The
meeting is closed to the public.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Development of Medications to Prevent and
Treat Opioid Use Disorders and Overdose
(UG3/UH3—Clinical Trials Optional).
Date: August 22, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4242, MSC 9550, Bethesda,
MD 20892, 301–827–5833, ivan.navarro@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: July 24, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–16021 Filed 7–26–19; 8:45 am]
BILLING CODE 4140–01–P
Dated: July 24, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–16020 Filed 7–26–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request National Cancer
Institute (NCI) a Generic Submission
for Formative Research, Pretesting and
Customer Satisfaction of NCI’s
Communication and Education
Resources (NCI); Correction
AGENCY:
Dated: July 24, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health,
HHS.
ACTION:
Notice; correction.
The Department of Health and
Human Services, National Institutes of
Health published a Notice in the
Federal Register on July 2, 2019. That
Notice requires a correction in the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Ilene French,
Branch Chief, Office of Communication
and Public Liaison, National Cancer
Institute, 9609 Medical Center Drive,
Maryland, 20892 or call non-toll-free
number (240) 276–7787 or Email your
request, including your address to:
nciocpl@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
[FR Doc. 2019–16013 Filed 7–26–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Amended Notice of
Meeting
Notice is hereby given of a change in
the meeting of the National Advisory
Council on Alcohol Abuse and
Alcoholism, September 19, 2019, 9:00
a.m. to September 19, 2019, 3:00 p.m.,
National Institutes of Health, National
Institute on Alcohol Abuse and
Alcoholism, 6700B Rockledge Drive,
Bethesda, MD 20817 which was
published in the Federal Register on
February 05, 2019, 84 FR 1757.
This meeting notice is amended to
change the meeting date from
September 19, 2019 to September 12,
Correction
In the Federal Register of July 2,
2019, in FR Doc. 2019–14071, on page
31605, correct the Estimated
Annualized Burden Hours table to read
as follows:
khammond on DSKBBV9HB2PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Type of
respondents
Focus Groups, Individual In-Depth Interviews, Brief Interviews, Surveys, Website Usability Testing.
Individuals .....
(General Public).
VerDate Sep<11>2014
16:54 Jul 26, 2019
Jkt 247001
PO 00000
Frm 00048
Fmt 4703
Number of
respondents
Sfmt 4703
Number of
responses per
respondent
9,000
E:\FR\FM\29JYN1.SGM
1
29JYN1
Average time
per response
(in hours)
45/60
Total annual
burden hours
6,750
]]>Agencies
[Federal Register Volume 84, Number 145 (Monday, July 29, 2019)]
[Notices]
[Page 36612]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16021]
[[Page 36612]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The cooperative agreement applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the cooperative agreement
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Development of Medications to Prevent and Treat
Opioid Use Disorders and Overdose (UG3/UH3--Clinical Trials
Optional).
Date: August 22, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: Hilton Washington/Rockville, 1750 Rockville Pike,
Rockville, MD 20852.
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892,
301-827-5833, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: July 24, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-16021 Filed 7-26-19; 8:45 am]
BILLING CODE 4140-01-P
